MX2021001764A - Terapia de combinacion. - Google Patents
Terapia de combinacion.Info
- Publication number
- MX2021001764A MX2021001764A MX2021001764A MX2021001764A MX2021001764A MX 2021001764 A MX2021001764 A MX 2021001764A MX 2021001764 A MX2021001764 A MX 2021001764A MX 2021001764 A MX2021001764 A MX 2021001764A MX 2021001764 A MX2021001764 A MX 2021001764A
- Authority
- MX
- Mexico
- Prior art keywords
- combination therapy
- inhibitor
- effective amount
- kinase
- methods
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 2
- 108091007960 PI3Ks Proteins 0.000 abstract 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862718925P | 2018-08-14 | 2018-08-14 | |
| PCT/US2019/046405 WO2020036995A1 (en) | 2018-08-14 | 2019-08-13 | Combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021001764A true MX2021001764A (es) | 2021-04-19 |
Family
ID=69525833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001764A MX2021001764A (es) | 2018-08-14 | 2019-08-13 | Terapia de combinacion. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210161909A1 (enExample) |
| JP (1) | JP2021534114A (enExample) |
| CN (1) | CN112839651A (enExample) |
| AU (1) | AU2019322858A1 (enExample) |
| EA (1) | EA202190360A1 (enExample) |
| IL (1) | IL280729A (enExample) |
| MX (1) | MX2021001764A (enExample) |
| TW (1) | TW202021592A (enExample) |
| WO (1) | WO2020036995A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3630118A4 (en) | 2017-05-23 | 2021-03-31 | MEI Pharma, Inc. | COMBINATION THERAPY |
| IL315315A (en) * | 2022-03-01 | 2024-10-01 | Mei Pharma Inc | Combined treatment with PI3K inhibitor and PD1 inhibitor |
| CN118949002A (zh) * | 2024-10-15 | 2024-11-15 | 杭州阿克索生物科技有限责任公司 | 一种宫颈癌细胞抑制组合物及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101209397B1 (ko) * | 2006-06-21 | 2012-12-06 | 피라말 라이프 사이언시스 리미티드 | 증식성 질환 치료용 광학이성적으로 순수한, 증식성 질환 치료용 플라본 유도체 및 이의 제조방법 |
| CN107501241B (zh) * | 2011-03-28 | 2020-10-13 | 梅制药公司 | 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途 |
| WO2014055647A1 (en) * | 2012-10-03 | 2014-04-10 | Mei Pharma, Inc. | (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases |
| WO2016024232A1 (en) * | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor |
| IL295472B2 (en) * | 2016-03-28 | 2024-10-01 | Presage Biosciences Inc | Pharmaceutical combinations for the treatment of cancer |
| CN109982687A (zh) * | 2016-09-19 | 2019-07-05 | 梅制药公司 | 联合疗法 |
| EP3630118A4 (en) * | 2017-05-23 | 2021-03-31 | MEI Pharma, Inc. | COMBINATION THERAPY |
| MX2020001727A (es) * | 2017-08-14 | 2020-03-20 | Mei Pharma Inc | Terapia de combinacion. |
-
2019
- 2019-08-13 WO PCT/US2019/046405 patent/WO2020036995A1/en not_active Ceased
- 2019-08-13 MX MX2021001764A patent/MX2021001764A/es unknown
- 2019-08-13 AU AU2019322858A patent/AU2019322858A1/en not_active Abandoned
- 2019-08-13 US US17/268,049 patent/US20210161909A1/en not_active Abandoned
- 2019-08-13 EA EA202190360A patent/EA202190360A1/ru unknown
- 2019-08-13 CN CN201980067618.0A patent/CN112839651A/zh active Pending
- 2019-08-13 JP JP2021506715A patent/JP2021534114A/ja active Pending
- 2019-08-14 TW TW108128842A patent/TW202021592A/zh unknown
-
2021
- 2021-02-08 IL IL280729A patent/IL280729A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020036995A1 (en) | 2020-02-20 |
| EA202190360A1 (ru) | 2021-07-15 |
| JP2021534114A (ja) | 2021-12-09 |
| US20210161909A1 (en) | 2021-06-03 |
| CN112839651A (zh) | 2021-05-25 |
| AU2019322858A1 (en) | 2021-04-01 |
| TW202021592A (zh) | 2020-06-16 |
| IL280729A (en) | 2021-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009773A (es) | Terapia de combinacion. | |
| MX2020001727A (es) | Terapia de combinacion. | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| MX2019001920A (es) | Arn la terapia contra el cancer. | |
| MX387885B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| MX2020004023A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| MX378263B (es) | Terapia de combinación para el tratamiento del cáncer. | |
| MX390121B (es) | Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas. | |
| MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
| MX2015014591A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. | |
| SG10201909199PA (en) | Method for treating cancer | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| MX340290B (es) | Uso terapéutico de un agonista de receptor tipo toll y terapia de combinación. | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| JOP20200014A1 (ar) | توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf | |
| EP4086250A3 (en) | Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| HK1250626A1 (zh) | 借助塞里班土单抗的组合治疗 | |
| EA202192964A1 (ru) | Комбинированная терапия | |
| MX2020008881A (es) | Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1. |